Freiburg, Germany

Dennis Wolf

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Location History:

  • Freiburg, DE (2017 - 2021)
  • Schopfheim, DE (2021)

Company Filing History:


Years Active: 2017-2021

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Dennis Wolf: Innovator in Targeted Therapeutics

Introduction

Dennis Wolf is a prominent inventor based in Freiburg, Germany. He has made significant contributions to the field of targeted therapeutics, particularly in the treatment of inflammation and atherogenesis. With a total of three patents to his name, his work has the potential to impact medical treatments significantly.

Latest Patents

Wolf's latest patents include innovative approaches to selectively target the CD40L/Mac-1 interaction using small peptide inhibitors. This invention focuses on the specific treatment of inflammation and atherogenesis, utilizing pharmaceutical compositions that comprise a polypeptide with the amino acid sequence EQLKKSKTL. Additionally, he has developed antibodies against Mac-1, which provide a means to inhibit the interaction of CD40L with activated Mac-1 without inducing integrin outside-in signaling.

Career Highlights

Throughout his career, Dennis Wolf has worked with notable institutions, including the Baker IDI Heart and Diabetes Institute and Universitätsklinikum Freiburg. His research has been pivotal in advancing our understanding of targeted therapies in cardiovascular and inflammatory diseases.

Collaborations

Wolf has collaborated with esteemed colleagues such as Andreas Zirlik and Karlheinz Peter, contributing to the advancement of research in his field.

Conclusion

Dennis Wolf's innovative work in targeted therapeutics exemplifies the potential of scientific research to address complex medical challenges. His patents and collaborations highlight his commitment to improving treatment options for patients suffering from inflammation and related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…